Cargando…
Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab
Current methods for subgroup analyses of data collected from randomized clinical trials (RCTs) may lead to false-positives from multiple testing, lack power to detect moderate but clinically meaningful differences, or be too simplistic in characterizing patients who may benefit from treatment. Herei...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936698/ https://www.ncbi.nlm.nih.gov/pubmed/29740627 http://dx.doi.org/10.1016/j.conctc.2017.01.007 |